Abcb1 Gene Polymorphisms Are Associated With Clinical Response To Nabiximols In Patients With Multiple Sclerosis-Related Spasticity
Gemma, A.; Mauri, M.; Banfi, P.; Versino, M.; Zollo, A.; Martinelli Boneschi, F.; Marino, F.; Cosentino, M.; Ferrari, M.
Show abstract
BackgroundMultiple Sclerosis (MS) is an autoimmune disease of the central nervous system causing severe symptoms, including spasticity-related pain. Nabiximols (NBX), a drug combining Tetrahydrocannabinol and Cannabidiol, is approved for MS-associated spasticity. Despite NBX efficacy, only 60-70% of patients respond to treatment. This study explores whether genetic polymorphisms in key genes involved in NBX pharmacology influence response to drug. Materials & MethodsThis is a genetic, exploratory study in which MS patients, treated with NBX, were retrospectively enrolled. Polymorphisms in genes related to NBX metabolism (CYP2C9, CYP2C19), efflux (ATP Binding Cassette subfamily B member 1 - ABCB1), and cannabinoid receptors (CNR1, CNR2) were analyzed using Real-Time PCR. ResultsAmong 45 enrolled patients, 29 responded to NBX and 16 did not. Of responders, 38% were homozygous for the T allele in ABCB1 1236C>T (rs1128503), and 48% for the T allele in ABCB1 3435A>T (rs1045642). None of the non-responders carried T allele. The odds ratios for response to NBX of TT homozygotes was 20.5 (95% CI:1.1-376.1, P=0.0039) for rs1128503 and 30.9 (95% CI:1.7-563.2, P=0.0006) for rs1045642. DiscussionThis study suggests a link between genetic profiles and NBX response. If validated in larger studies, these findings could pave the way for personalized therapy for MS-related spasticity.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Masitinib Limits Neuronal Damage, as Measured by Serum Neurofilament Light Chain Concentration, in a Model of Neuroimmune-Driven Neurodegenerative Disease 93%
- A prospective, observational study on conversion of Clinically Isolated Syndrome to Multiple Sclerosis during 4-year period (MS NEO study) in Taiwan 93%
- Olfactory Dysfunction in Patients with Multiple Sclerosis; A Systematic Review and Meta-Analysis 93%
Similar papers in this journal
- Cannabidivarin for the treatment of HIV-associated neuropathic pain: a randomized, blinded, controlled clinical trial 90%
- SLCO1B1 functional variants and statin-induced myopathy in people with recent genealogical ancestors from Africa: a population-based real-world study 89%
- Investigation of genomic and transcriptomic risk factors in clopidogrel response in African Americans 88%
Similar papers in this journal
- Structural variability, expression profile and pharmacogenetics properties of TMPRSS2 gene as a potential target for COVID-19 therapy 90%
- A novel co-segregating DCTN1 splice site variant in a family with Bipolar Disorder may hold the key to understanding the etiology 90%
- Reduced Expression of Slc Genes in the VTA and NAcc of Male Mice with Positive Fighting Experience 89%
Similar papers in this journal
- Correlates of patient-reported cognitive performance with regard to disability 93%
- Immunomodulatory Therapy with Glatiramer Acetate Reduces Endoplasmic Reticulum Stress and Mitochondrial Dysfunction in Experimental Autoimmune Encephalomyelitis 93%
- MeCP2 deficiency exacerbates the neuroinflammatory setting and autoreactive response during an autoimmune challenge: implications for Rett Syndrome. 92%
Similar papers in this journal
- Differential effects of IL4I1 protein on lymphocytes from healthy and multiple sclerosis patients 91%
- Suspected Adverse Drug Reactions of the Type 2 Antidiabetic Drug Class Dipeptidyl-Peptidase IV inhibitors (DPP4i): Can polypharmacology help explain? 89%
- Declines, and Pronounced Regional Disparities, in Meperidine Use in the United States 88%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.